<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00513292</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00341</org_study_id>
    <secondary_id>NCI-2009-00341</secondary_id>
    <secondary_id>CDR0000559039</secondary_id>
    <secondary_id>ACOSOG-Z1041</secondary_id>
    <secondary_id>Z1041</secondary_id>
    <secondary_id>ACOSOG-Z1041</secondary_id>
    <secondary_id>U10CA012027</secondary_id>
    <nct_id>NCT00513292</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery</brief_title>
  <official_title>A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed by Paclitaxel Plus Trastuzumab With a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Patients With HER-2 Positive Operable Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This randomized phase III trial is studying giving fluorouracil together with epirubicin and
      cyclophosphamide followed by paclitaxel and trastuzumab to see how well it works compared
      with giving paclitaxel together with trastuzumab followed by fluorouracil, epirubicin,
      cyclophosphamide, and trastuzumab in treating women with palpable breast cancer that can be
      removed by surgery. Drugs used in chemotherapy work in different ways to stop the growth of
      tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal
      antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the
      ability of tumor cells to grow and spread. Others find tumor cells and help kill them or
      carry tumor-killing substances to them. It is not yet known whether it is more effective to
      give combination chemotherapy before or after treatment with paclitaxel plus trastuzumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. The primary objective of this study is to compare the pathologic complete response rate
      (pCR) within the breast of a sequential regimen of concurrent weekly paclitaxel and
      trastuzumab, followed by continued weekly trastuzumab administered concurrently with FEC-75
      (Arm 2), to the pCR rate of a sequential regimen of FEC-75 alone followed by concurrent
      weekly paclitaxel and trastuzumab (Arm 1).

      SECONDARY OBJECTIVES:

      I. To estimate the cardiotoxicity of a sequential regimen of concurrent weekly paclitaxel and
      trastuzumab, followed by continued weekly trastuzumab administered concurrently with FEC-75,
      followed postoperatively by q 3 week trastuzumab for a total duration of trastuzumab therapy
      through 52 weeks from the first dose (Arm 2), and compare the cardiotoxicity to that of a
      sequential regimen of FEC-75 alone followed by concurrent weekly paclitaxel and trastuzumab,
      followed by q 3 week trastuzumab for a total duration of trastuzumab therapy through 52 weeks
      from the first dose (Arm 1).

      II. To compare the combined pCR rate in the breast and ipsilateral axilla obtained with the
      two regimens evaluated in this study.

      III. To compare the clinical response rates (cRR) of the two regimens evaluated in this
      study.

      IV. To compare the non-cardiac toxicity of the two regimens evaluated in this study.

      V. To compare breast conservation rates achieved with the two regimens evaluated in this
      study.

      VI. To evaluate disease-free survival and overall survival at 5 years post-randomization.

      VII. To correlate pCR rate with potential molecular markers of response.

      OUTLINE: Patients are stratified by clinical tumor size (breast tumor size &lt; 2 cm and nodal
      metastases &lt; 2 cm vs breast tumor size &lt; 2 cm and nodal metastases ≥ 2 cm vs breast tumor
      size 2-4 cm [any nodal status] vs breast tumor size ≥ 4 cm [any nodal status]), age (&lt; 50 vs
      ≥ 50) and hormone receptor status (estrogen receptor [ER]- and progesterone receptor
      [PgR]-negative vs ER- and/or PgR-positive). Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive FEC comprising fluoroucacil intravenously (IV), epirubicin
      hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4
      courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once
      weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after
      completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after
      surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks.

      ARM II: Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12
      weeks. Beginning 7 days after completion of paclitaxel and trastuzumab, patients receive FEC
      comprising fluoroucacil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment
      repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an
      additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo
      surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I.

      After completion of study therapy, patients are followed every 3 months for 1 year and then
      every 6 months for 4 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2007</start_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pCR Within the Breast, Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Pathological complete response (pCR) rates will be based on institutional pathology reports. In the final analysis for publication, rates will be based on blinded central review of these institutional pathology reports. The Chi-squared test will be conducted at the two-sided 0.05 level. A 95% confidence interval will be computed for the difference in pCR rates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combined pCR Rate in the Breast and Axillary Lymph Nodes Defined as no Evidence of Invasive Tumor Remaining in Either the Breast or Axillary Nodes at Surgery Following Completion of Chemotherapy</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>pCR Rate in the Breast and Axillary Lymph Nodes Defined as no Evidence of Invasive Tumor Remaining in Either the Breast or Axillary Nodes at Surgery Following Completion of Chemotherapy (among those with Metastasis to movable ipsilateral axillary lymph node(s) (cN1-3) disease).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asymptomatic Decreases From Baseline in Left Ventricular Ejection Fraction (LVEF) at Week 12</measure>
    <time_frame>Baseline, at 12 week</time_frame>
    <description>The summary of asymptomatic decrease in LVEF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asymptomatic Decreases From Baseline in LVEF at Week 24</measure>
    <time_frame>Baseline, at 24 week</time_frame>
    <description>The summary of asymptomatic changed in LVEF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEFs From Regularly Scheduled Multi Gated Acquisition Scan (MUGA)/Echo Scans as Reported at 12 Week</measure>
    <time_frame>At 12 week</time_frame>
    <description>All patients who had a MUGA or ECHO performed at week 12 are included in the summary of asymptomatic changed in LVEF at week 12. Difference from pretreatment LVEF (%) at 12 weeks [median change from baseline Inter Quartile Range (IQR)].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LVEFs (From Regularly Scheduled Multi Gated Acquisition Scan (MUGA)/Echo Scans) From Baseline and at 24 Week</measure>
    <time_frame>Baseline, at 24 week</time_frame>
    <description>Difference from pretreatment LVEF (%) at 24 weeks [median change from baseline Inter Quartile Range (IQR)].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast Conservation Rates</measure>
    <time_frame>From time surgery to up to 5 years</time_frame>
    <description>Method of definitive surgery, categorized as breast conserving surgery (&quot;lumpectomy&quot;) or total mastectomy. Breast conservation rates will be compared using the Mantel-Haenszel test, stratified by tumor size (2.0 -4.0 cm, &gt; 4.0 cm), age (&lt; 50, &gt;= 50) and hormone receptor status (ER- and PgR-negative, ER- and/or PgR positive). The Chi-squared will be conducted at the two-sided .05 level. A 95% confidence interval will be computed for the difference in breast conservation rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival (DFS)</measure>
    <time_frame>From time to registration to time of event, assessed up to 5 years</time_frame>
    <description>DFS defined as inoperable progressive disease, gross residual disease following definitive surgery, local, regional or distant recurrence, contralateral breast cancer, other second primary cancers, and death prior to recurrence or second primary cancer. DFS of Arm I and Arm II patients will be estimated using the Kaplan-Meier method. The difference will be tested using the log-rank test, stratified by tumor size (2.0 - 4.0 cm, &gt; 4.0 cm), age (&lt; 50, &gt;= 50), and hormone receptor status (ER- and PgR-negative, ER- and/or PgR-positive).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From time to registration to death, assessed up to 5 years</time_frame>
    <description>OS of Arm I and Arm II patients will be estimated using the Kaplan-Meier method. The difference will be tested using the log-rank test, stratified by tumor size (2.0 - 4.0 cm, &gt; 4.0 cm), age (&lt; 50, &gt;= 50), and hormone receptor status (ER- and PgR-negative, ER- and/or PgR-positive).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">280</enrollment>
  <condition>HER2/Neu Positive</condition>
  <condition>Stage IA Breast Cancer</condition>
  <condition>Stage IB Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <arm_group>
    <arm_group_label>FEC-75 then Paclitaxel/trastuzumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive FEC comprising fluoroucacil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel/trastuzumab then trastuzumab/FEC-75</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluoroucacil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>FEC-75 then Paclitaxel/trastuzumab</arm_group_label>
    <arm_group_label>Paclitaxel/trastuzumab then trastuzumab/FEC-75</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>FEC-75 then Paclitaxel/trastuzumab</arm_group_label>
    <arm_group_label>Paclitaxel/trastuzumab then trastuzumab/FEC-75</arm_group_label>
    <other_name>Ellence</other_name>
    <other_name>IMI-28</other_name>
    <other_name>Pharmorubicin PFS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>FEC-75 then Paclitaxel/trastuzumab</arm_group_label>
    <arm_group_label>Paclitaxel/trastuzumab then trastuzumab/FEC-75</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>FEC-75 then Paclitaxel/trastuzumab</arm_group_label>
    <arm_group_label>Paclitaxel/trastuzumab then trastuzumab/FEC-75</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>Bristaxol</other_name>
    <other_name>Praxel</other_name>
    <other_name>Taxol</other_name>
    <other_name>Taxol Konzentrat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Therapeutic Conventional Surgery</intervention_name>
    <description>Undergo surgery</description>
    <arm_group_label>FEC-75 then Paclitaxel/trastuzumab</arm_group_label>
    <arm_group_label>Paclitaxel/trastuzumab then trastuzumab/FEC-75</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>FEC-75 then Paclitaxel/trastuzumab</arm_group_label>
    <arm_group_label>Paclitaxel/trastuzumab then trastuzumab/FEC-75</arm_group_label>
    <other_name>ABP 980</other_name>
    <other_name>Anti-c-ERB-2</other_name>
    <other_name>Anti-c-erbB2 Monoclonal Antibody</other_name>
    <other_name>Anti-ERB-2</other_name>
    <other_name>Anti-erbB-2</other_name>
    <other_name>Anti-erbB2 Monoclonal Antibody</other_name>
    <other_name>Anti-HER2/c-erbB2 Monoclonal Antibody</other_name>
    <other_name>Anti-p185-HER2</other_name>
    <other_name>c-erb-2 Monoclonal Antibody</other_name>
    <other_name>HER2 Monoclonal Antibody</other_name>
    <other_name>Herceptin</other_name>
    <other_name>Herceptin Biosimilar PF-05280014</other_name>
    <other_name>Herceptin Trastuzumab Biosimilar PF-05280014</other_name>
    <other_name>MoAb HER2</other_name>
    <other_name>Monoclonal Antibody c-erb-2</other_name>
    <other_name>Monoclonal Antibody HER2</other_name>
    <other_name>PF-05280014</other_name>
    <other_name>rhuMAb HER2</other_name>
    <other_name>Trastuzumab Biosimilar ABP 980</other_name>
    <other_name>Trastuzumab Biosimilar PF-05280014</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of invasive adenocarcinoma by core needle biopsy

               -  Fine needle aspiration allowed provided primary tumor size &lt; 2 cm and lymph node
                  metastases are present

               -  Excisional biopsy of the primary tumor allowed provided biopsy-positive lymph
                  nodes are present

          -  Primary tumor ≥ 2 cm and/or ≥ 1 biopsy-positive lymph node

          -  HER2-positive disease

               -  Confirmation by fluorescent in situ hybridization (FISH) requires gene
                  amplification

               -  Confirmation by immunohistochemistry (IHC) requires a strongly positive (3+)
                  staining intensity score

          -  Ductal carcinoma in situ (DCIS) or synchronous DCIS of the contralateral breast
             regardless of prior therapy allowed

               -  Synchronous invasive breast cancer not allowed

          -  Ipsilateral DCIS treated by local excision with or without hormonal therapy allowed

               -  Those treated with radiation therapy are not allowed

          -  No definitive clinical or radiologic evidence of metastatic disease

          -  No history of invasive breast cancer

          -  Hormone receptor status known

          -  Menopausal status not specified

          -  ECOG performance status of 0 -1

          -  Absolute neutrophil count ≥ 1,200/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Total bilirubin normal unless the patient has a grade 1 bilirubin elevation (normal to
             1.5 times upper limit of normal [ULN]) resulting from Gilbert disease or similar
             syndrome due to slow conjugation of bilirubin

          -  Alkaline phosphatase ≤ 2.5 times ULN

          -  AST ≤ 1.5 times ULN

          -  Creatinine normal

          -  Left ventricular ejection fraction (LVEF) ≥ 55 by multi gated acquisition scan (MUGA)
             or echocardiogram (ECHO) within the past 3 months

          -  Patients with either skeletal pain or alkaline phosphatase that is &gt; ULN but ≤ 2.5
             times ULN allowed if bone scans fail to demonstrate metastatic disease

               -  Suspicious findings on bone scan must be confirmed as benign by x-ray, MRI, or
                  biopsy

          -  Prior non-breast malignancies allowed if disease-free for 5 years since completion of
             initial treatment regimen and deemed by their physician to be at low risk for
             recurrence

               -  Patients who had the following cancers are eligible if diagnosed and treated
                  within the past 5 years:

                    -  Carcinoma in situ of the cervix

                    -  Colon carcinoma in situ

                    -  Melanoma in situ

                    -  Basal cell and squamous cell carcinoma of the skin

          -  No cardiac disease that would preclude the use of epirubicin hydrochloride or
             trastuzumab (Herceptin®) including any of the following:

               -  Active cardiac disease

               -  Angina pectoris that requires the use of antianginal medication

               -  Cardiac arrhythmia requiring medication

               -  Severe conduction abnormality

               -  Clinically significant valvular disease

               -  Cardiomegaly on chest x-ray

               -  Ventricular hypertrophy on EKG

               -  Patient's with poorly controlled hypertension ( i.e., diastolic greater than 100
                  mm/Hg)

                    -  Patients with hypertension that is well controlled on medication are
                       eligible

               -  History of cardiac disease

               -  Myocardial infarction documented as a clinical diagnosis or by EKG or any other
                  tests

               -  Documented congestive heart failure

               -  Documented cardiomyopathy

          -  No sensory or motor neuropathy ≥ grade 2, as defined by the NCI's CTCAE v3.0

          -  Women of reproductive potential must agree to use an effective non-hormonal method of
             contraception during therapy

          -  Women of child bearing potential must have a negative urine or serum pregnancy test
             within 2 weeks of registration

          -  Not pregnant or nursing

          -  No psychiatric or addictive disorders or other conditions that, in the opinion of the
             investigator, would preclude the patient from meeting the study requirements

          -  No non-malignant systemic disease (e.g., cardiovascular, renal, hepatic) that would
             preclude treatment with either of the treatment regimens

          -  No prior surgical axillary staging procedure

               -  Prior non-excisional biopsy of an axillary node allowed

          -  No prior treatment for this breast cancer

               -  Hormonal therapy allowed if had been given for up to a total of 28 days anytime
                  after diagnosis and before study entry

               -  Hormonal therapy must stop at or before study entry and be re-started, if
                  indicated, following surgery

          -  No prior therapy with anthracyclines or taxanes for any malignancy

          -  No other investigational agents within the past 30 days

          -  No concurrent sex hormonal therapy (e.g., birth control pills, ovarian hormonal
             replacement therapy)

          -  No concurrent therapy with any hormonal agent such as raloxifene, tamoxifen, or other
             selective estrogen receptor modulator (SERM), either for osteoporosis or breast cancer
             prevention
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aman Buzdar</last_name>
    <role>Principal Investigator</role>
    <affiliation>American College of Surgeons</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama Mitchell Cancer Institute</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36688</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eden Hospital Medical Center</name>
      <address>
        <city>Castro Valley</city>
        <state>California</state>
        <zip>94546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marin Cancer Care Inc</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Rose Hospital</name>
      <address>
        <city>Hayward</city>
        <state>California</state>
        <zip>94545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Care Health System - Pleasanton</name>
      <address>
        <city>Pleasanton</city>
        <state>California</state>
        <zip>94588</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Medical Oncology Consultants</name>
      <address>
        <city>Pleasanton</city>
        <state>California</state>
        <zip>94588</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morton Plant Hospital</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward Health Medical Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeland Regional Cancer Center</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Medical Center</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presence Resurrection Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Francis Hospital and Health Centers</name>
      <address>
        <city>Beech Grove</city>
        <state>Indiana</state>
        <zip>46107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan Saint Francis Health-Indianapolis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reid Hospital and Health Care Services</name>
      <address>
        <city>Richmond</city>
        <state>Indiana</state>
        <zip>47374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siouxland Regional Cancer Center</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center-Sioux City</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Regional Medical Center</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas - Chanute</name>
      <address>
        <city>Chanute</city>
        <state>Kansas</state>
        <zip>66720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas - Dodge City</name>
      <address>
        <city>Dodge City</city>
        <state>Kansas</state>
        <zip>67801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas - El Dorado</name>
      <address>
        <city>El Dorado</city>
        <state>Kansas</state>
        <zip>67042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas - Fort Scott</name>
      <address>
        <city>Fort Scott</city>
        <state>Kansas</state>
        <zip>66701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas-Independence</name>
      <address>
        <city>Independence</city>
        <state>Kansas</state>
        <zip>67301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas-Kingman</name>
      <address>
        <city>Kingman</city>
        <state>Kansas</state>
        <zip>67068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawrence Memorial Hospital</name>
      <address>
        <city>Lawrence</city>
        <state>Kansas</state>
        <zip>66044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas-Liberal</name>
      <address>
        <city>Liberal</city>
        <state>Kansas</state>
        <zip>67901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas - Newton</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas - Parsons</name>
      <address>
        <city>Parsons</city>
        <state>Kansas</state>
        <zip>67357</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas - Pratt</name>
      <address>
        <city>Pratt</city>
        <state>Kansas</state>
        <zip>67124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas - Salina</name>
      <address>
        <city>Salina</city>
        <state>Kansas</state>
        <zip>67401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas - Wellington</name>
      <address>
        <city>Wellington</city>
        <state>Kansas</state>
        <zip>67152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates In Womens Health</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas-Wichita Medical Arts Tower</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas - Main Office</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Via Christi Regional Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wesley Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wichita CCOP</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas - Winfield</name>
      <address>
        <city>Winfield</city>
        <state>Kansas</state>
        <zip>67156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Health Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The James Graham Brown Cancer Center at University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unspecified Site</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borgess Medical Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Michigan Cancer Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Essentia Health Cancer Center</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Essentia Health Saint Mary's Medical Center</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miller-Dwan Hospital</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singing River Hospital</name>
      <address>
        <city>Pascagoula</city>
        <state>Mississippi</state>
        <zip>39581</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Research Foundation CCOP</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunrise Hospital and Medical Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portsmouth Regional Hospital</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Barnabas Medical Center</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMDNJ - New Jersey Medical School</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Regional Medical Center</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Kaseman Hospital</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange Regional Medical Center</name>
      <address>
        <city>Middletown</city>
        <state>New York</state>
        <zip>10940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MidHudson Regional Hospital of Westchester Medical Center</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staten Island University Hospital</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Women's Cancer Centers-Asheville</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne Memorial Hospital</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Rutan Hospital</name>
      <address>
        <city>Bellefontaine</city>
        <state>Ohio</state>
        <zip>43311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aultman Health Foundation</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adena Regional Medical Center</name>
      <address>
        <city>Chillicothe</city>
        <state>Ohio</state>
        <zip>45601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus CCOP</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grant Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Carmel Health Center West</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctors Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grandview Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital - Dayton</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Valley Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samaritan North Health Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton CCOP</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veteran Affairs Medical Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45428</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Delaware</city>
        <state>Ohio</state>
        <zip>43015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blanchard Valley Hospital</name>
      <address>
        <city>Findlay</city>
        <state>Ohio</state>
        <zip>45840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium Medical Center-Middletown Regional Hospital</name>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <zip>45005-1066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne Hospital</name>
      <address>
        <city>Greenville</city>
        <state>Ohio</state>
        <zip>45331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kettering Medical Center</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairfield Medical Center</name>
      <address>
        <city>Lancaster</city>
        <state>Ohio</state>
        <zip>43130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marietta Memorial Hospital</name>
      <address>
        <city>Marietta</city>
        <state>Ohio</state>
        <zip>45750</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knox Community Hospital</name>
      <address>
        <city>Mount Vernon</city>
        <state>Ohio</state>
        <zip>43050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Licking Memorial Hospital</name>
      <address>
        <city>Newark</city>
        <state>Ohio</state>
        <zip>43055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Ohio Medical Center</name>
      <address>
        <city>Portsmouth</city>
        <state>Ohio</state>
        <zip>45662</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Springfield Regional Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Ohio</state>
        <zip>45505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upper Valley Medical Center</name>
      <address>
        <city>Troy</city>
        <state>Ohio</state>
        <zip>45373</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Ann's Hospital</name>
      <address>
        <city>Westerville</city>
        <state>Ohio</state>
        <zip>43081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinton Memorial Hospital</name>
      <address>
        <city>Wilmington</city>
        <state>Ohio</state>
        <zip>45177</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greene Memorial Hospital</name>
      <address>
        <city>Xenia</city>
        <state>Ohio</state>
        <zip>45385</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis HealthCare System</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of Southwest Oklahoma Research</name>
      <address>
        <city>Lawton</city>
        <state>Oklahoma</state>
        <zip>73505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's University Hospital-Bethlehem Campus</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee - Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Breast Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meharry Medical College</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Don and Sybil Harrington Cancer Center</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkland Memorial Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zale Lipshy University Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clements University Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern/Simmons Cancer Center-Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctor's Hospital of Laredo</name>
      <address>
        <city>Laredo</city>
        <state>Texas</state>
        <zip>78041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covenant Medical Center-Lakeside</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danville Regional Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <zip>24541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Port Warwick</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center-First Hill</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122-4307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gundersen Lutheran Medical Center</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oconomowoc Memorial Hospital-ProHealth Care Inc</name>
      <address>
        <city>Oconomowoc</city>
        <state>Wisconsin</state>
        <zip>53066-3896</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waukesha Memorial Hospital</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan City Hospital</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2007</study_first_submitted>
  <study_first_submitted_qc>August 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2007</study_first_posted>
  <results_first_submitted>July 14, 2015</results_first_submitted>
  <results_first_submitted_qc>August 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 29, 2015</results_first_posted>
  <last_update_submitted>November 14, 2016</last_update_submitted>
  <last_update_submitted_qc>November 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Total Enrolled: 282, 2 patients withdrew consent before starting treatment, 280 patients started the treatment and are eligible for primary analysis.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>FEC-75 Then Paclitaxel/Trastuzumab</title>
          <description>Patients receive FEC comprising fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="P2">
          <title>Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75</title>
          <description>Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="138"/>
                <participants group_id="P2" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="138"/>
                <participants group_id="P2" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Total enrolled: 282, 2 withdrew consent before start of treatment</population>
      <group_list>
        <group group_id="B1">
          <title>FEC-75 Then Paclitaxel/Trastuzumab</title>
          <description>Patients receive FEC comprising fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="B2">
          <title>Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75</title>
          <description>Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="138"/>
            <count group_id="B2" value="142"/>
            <count group_id="B3" value="280"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" lower_limit="32" upper_limit="76"/>
                    <measurement group_id="B2" value="48" lower_limit="28" upper_limit="73"/>
                    <measurement group_id="B3" value="50" lower_limit="28" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="280"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>pCR Within the Breast, Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy</title>
        <description>Pathological complete response (pCR) rates will be based on institutional pathology reports. In the final analysis for publication, rates will be based on blinded central review of these institutional pathology reports. The Chi-squared test will be conducted at the two-sided 0.05 level. A 95% confidence interval will be computed for the difference in pCR rates.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>All patients who started study treatment are included in the analysis of the primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>FEC-75 Then Paclitaxel/Trastuzumab</title>
            <description>Patients receive Fluorouracil, epirubicin, and cyclophosphamide (FEC) comprising fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75</title>
            <description>Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>pCR Within the Breast, Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy</title>
          <description>Pathological complete response (pCR) rates will be based on institutional pathology reports. In the final analysis for publication, rates will be based on blinded central review of these institutional pathology reports. The Chi-squared test will be conducted at the two-sided 0.05 level. A 95% confidence interval will be computed for the difference in pCR rates.</description>
          <population>All patients who started study treatment are included in the analysis of the primary endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.5" lower_limit="47.8" upper_limit="64.9"/>
                    <measurement group_id="O2" value="54.2" lower_limit="45.7" upper_limit="62.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The difference in pCR rates between treatment arms for pCR within the Breast, Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.7</p_value>
            <method>Chi-squared</method>
            <param_type>difference in percentages between arms</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.3</ci_lower_limit>
            <ci_upper_limit>13.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Combined pCR Rate in the Breast and Axillary Lymph Nodes Defined as no Evidence of Invasive Tumor Remaining in Either the Breast or Axillary Nodes at Surgery Following Completion of Chemotherapy</title>
        <description>pCR Rate in the Breast and Axillary Lymph Nodes Defined as no Evidence of Invasive Tumor Remaining in Either the Breast or Axillary Nodes at Surgery Following Completion of Chemotherapy (among those with Metastasis to movable ipsilateral axillary lymph node(s) (cN1-3) disease).</description>
        <time_frame>Up to 5 years</time_frame>
        <population>All patients who had clinical N1-3 disease prior to the start of treatment are included in the analysis of the pCR rate in the breast and axillary lymph nodes.</population>
        <group_list>
          <group group_id="O1">
            <title>FEC-75 Then Paclitaxel/Trastuzumab</title>
            <description>Patients receive Fluorouracil, epirubicin, and cyclophosphamide (FEC) comprising fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75</title>
            <description>Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Combined pCR Rate in the Breast and Axillary Lymph Nodes Defined as no Evidence of Invasive Tumor Remaining in Either the Breast or Axillary Nodes at Surgery Following Completion of Chemotherapy</title>
          <description>pCR Rate in the Breast and Axillary Lymph Nodes Defined as no Evidence of Invasive Tumor Remaining in Either the Breast or Axillary Nodes at Surgery Following Completion of Chemotherapy (among those with Metastasis to movable ipsilateral axillary lymph node(s) (cN1-3) disease).</description>
          <population>All patients who had clinical N1-3 disease prior to the start of treatment are included in the analysis of the pCR rate in the breast and axillary lymph nodes.</population>
          <units>Percentage (95% confidence Interval)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3" lower_limit="37.6" upper_limit="59.2"/>
                    <measurement group_id="O2" value="46.7" lower_limit="36.4" upper_limit="56.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asymptomatic Decreases From Baseline in Left Ventricular Ejection Fraction (LVEF) at Week 12</title>
        <description>The summary of asymptomatic decrease in LVEF.</description>
        <time_frame>Baseline, at 12 week</time_frame>
        <population>All patients who had a MUGA or ECHO performed at week 12 are included in the summary of asymptomatic changed in LVEF at week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>FEC-75 Then Paclitaxel/Trastuzumab</title>
            <description>Patients receive Fluorouracil, epirubicin, and cyclophosphamide (FEC) comprising fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75</title>
            <description>Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Asymptomatic Decreases From Baseline in Left Ventricular Ejection Fraction (LVEF) at Week 12</title>
          <description>The summary of asymptomatic decrease in LVEF.</description>
          <population>All patients who had a MUGA or ECHO performed at week 12 are included in the summary of asymptomatic changed in LVEF at week 12.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>no decrease or decrease &lt; 10%, still above LLN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3"/>
                    <measurement group_id="O2" value="82.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>decrease &lt; 10%, below lower limit of normal (LLN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>decrease 10-15%, still above lower limit of normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2"/>
                    <measurement group_id="O2" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>decrease 10-15%, below lower limit of normal (LLN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>decrease &gt; 15%, still above lower limit of norm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>decrease &gt; 15%, below lower limit of normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asymptomatic Decreases From Baseline in LVEF at Week 24</title>
        <description>The summary of asymptomatic changed in LVEF.</description>
        <time_frame>Baseline, at 24 week</time_frame>
        <population>All patients who had a MUGA or ECHO performed at week 24 are included in the summary of asymptomatic changed in LVEF at week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>FEC-75 Then Paclitaxel/Trastuzumab</title>
            <description>Patients receive Fluorouracil, epirubicin, and cyclophosphamide (FEC) comprising fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75</title>
            <description>Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Asymptomatic Decreases From Baseline in LVEF at Week 24</title>
          <description>The summary of asymptomatic changed in LVEF.</description>
          <population>All patients who had a MUGA or ECHO performed at week 24 are included in the summary of asymptomatic changed in LVEF at week 24.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>no decrease or decrease &lt; 10%, still above LLN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                    <measurement group_id="O2" value="73.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>decrease &lt; 10%, below lower limit of normal (LLN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>decrease 10-15%, still above lower limit of normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9"/>
                    <measurement group_id="O2" value="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>decrease 10-15%, below lower limit of normal (LLN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>decrease &gt; 15%, still above lower limit of normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>decrease &gt; 15%, below lower limit of normal (LLN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LVEFs From Regularly Scheduled Multi Gated Acquisition Scan (MUGA)/Echo Scans as Reported at 12 Week</title>
        <description>All patients who had a MUGA or ECHO performed at week 12 are included in the summary of asymptomatic changed in LVEF at week 12. Difference from pretreatment LVEF (%) at 12 weeks [median change from baseline Inter Quartile Range (IQR)].</description>
        <time_frame>At 12 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FEC-75 Then Paclitaxel/Trastuzumab</title>
            <description>Patients receive Fluorouracil, epirubicin, and cyclophosphamide (FEC) comprising fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75</title>
            <description>Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>LVEFs From Regularly Scheduled Multi Gated Acquisition Scan (MUGA)/Echo Scans as Reported at 12 Week</title>
          <description>All patients who had a MUGA or ECHO performed at week 12 are included in the summary of asymptomatic changed in LVEF at week 12. Difference from pretreatment LVEF (%) at 12 weeks [median change from baseline Inter Quartile Range (IQR)].</description>
          <units>percent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="-5" upper_limit="2"/>
                    <measurement group_id="O2" value="-3" lower_limit="-7" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in LVEFs (From Regularly Scheduled Multi Gated Acquisition Scan (MUGA)/Echo Scans) From Baseline and at 24 Week</title>
        <description>Difference from pretreatment LVEF (%) at 24 weeks [median change from baseline Inter Quartile Range (IQR)].</description>
        <time_frame>Baseline, at 24 week</time_frame>
        <population>All patients who had a MUGA or ECHO performed at week 24 are included in the summary of asymptomatic changed in LVEF at week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>FEC-75 Then Paclitaxel/Trastuzumab</title>
            <description>Patients receive Fluorouracil, epirubicin, and cyclophosphamide (FEC) comprising fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75</title>
            <description>Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Change in LVEFs (From Regularly Scheduled Multi Gated Acquisition Scan (MUGA)/Echo Scans) From Baseline and at 24 Week</title>
          <description>Difference from pretreatment LVEF (%) at 24 weeks [median change from baseline Inter Quartile Range (IQR)].</description>
          <population>All patients who had a MUGA or ECHO performed at week 24 are included in the summary of asymptomatic changed in LVEF at week 24.</population>
          <units>percent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" lower_limit="-7" upper_limit="0"/>
                    <measurement group_id="O2" value="-4" lower_limit="-9" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Breast Conservation Rates</title>
        <description>Method of definitive surgery, categorized as breast conserving surgery (“lumpectomy”) or total mastectomy. Breast conservation rates will be compared using the Mantel-Haenszel test, stratified by tumor size (2.0 -4.0 cm, &gt; 4.0 cm), age (&lt; 50, &gt;= 50) and hormone receptor status (ER- and PgR-negative, ER- and/or PgR positive). The Chi-squared will be conducted at the two-sided .05 level. A 95% confidence interval will be computed for the difference in breast conservation rates.</description>
        <time_frame>From time surgery to up to 5 years</time_frame>
        <posting_date>06/2017</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival (DFS)</title>
        <description>DFS defined as inoperable progressive disease, gross residual disease following definitive surgery, local, regional or distant recurrence, contralateral breast cancer, other second primary cancers, and death prior to recurrence or second primary cancer. DFS of Arm I and Arm II patients will be estimated using the Kaplan-Meier method. The difference will be tested using the log-rank test, stratified by tumor size (2.0 - 4.0 cm, &gt; 4.0 cm), age (&lt; 50, &gt;= 50), and hormone receptor status (ER- and PgR-negative, ER- and/or PgR-positive).</description>
        <time_frame>From time to registration to time of event, assessed up to 5 years</time_frame>
        <posting_date>06/2017</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS of Arm I and Arm II patients will be estimated using the Kaplan-Meier method. The difference will be tested using the log-rank test, stratified by tumor size (2.0 - 4.0 cm, &gt; 4.0 cm), age (&lt; 50, &gt;= 50), and hormone receptor status (ER- and PgR-negative, ER- and/or PgR-positive).</description>
        <time_frame>From time to registration to death, assessed up to 5 years</time_frame>
        <posting_date>06/2017</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm A</title>
          <description>Patients receive FEC comprising fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="E2">
          <title>Arm B</title>
          <description>Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="138"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Extraocular muscle paresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Eyelid function disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Anal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Colonic hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="138"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="138"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Ear, nose and throat examination abnormal</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="138"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="138"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="23" subjects_affected="13" subjects_at_risk="138"/>
                <counts group_id="E2" events="23" subjects_affected="17" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="138"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Peripheral nerve infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Dermatitis radiation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Leukocyte count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="138"/>
                <counts group_id="E2" events="20" subjects_affected="13" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Serum cholesterol increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkalosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="138"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Neurological disorder NOS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="138"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Taste alteration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Irregular menstruation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="138"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hemorrhage nasal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Voice alteration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="138"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hand-and-foot syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Rash desquamating</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 9</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood disorder</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="279" subjects_affected="53" subjects_at_risk="138"/>
                <counts group_id="E2" events="269" subjects_affected="50" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="8" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Lymphatic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Thrombotic microangiopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="138"/>
                <counts group_id="E2" events="25" subjects_affected="18" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="138"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Premature ventricular contractions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="138"/>
                <counts group_id="E2" events="14" subjects_affected="8" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="14" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="9" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>External ear inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>External ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hearing loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Middle ear inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dry eye syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Extraocular muscle paresis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="17" subjects_affected="9" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Eyelid function disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="138"/>
                <counts group_id="E2" events="37" subjects_affected="16" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Watering eyes</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="9" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="138"/>
                <counts group_id="E2" events="24" subjects_affected="16" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Anal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Anal mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="142" subjects_affected="57" subjects_at_risk="138"/>
                <counts group_id="E2" events="113" subjects_affected="51" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="172" subjects_affected="72" subjects_at_risk="138"/>
                <counts group_id="E2" events="210" subjects_affected="79" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="48" subjects_affected="16" subjects_at_risk="138"/>
                <counts group_id="E2" events="52" subjects_affected="24" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="138"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Ear, nose and throat examination abnormal</sub_title>
                <counts group_id="E1" events="86" subjects_affected="46" subjects_at_risk="138"/>
                <counts group_id="E2" events="78" subjects_affected="41" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Endoscopy large bowel abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Esophageal mucositis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Gastric mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="31" subjects_affected="21" subjects_at_risk="138"/>
                <counts group_id="E2" events="31" subjects_affected="17" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="325" subjects_affected="101" subjects_at_risk="138"/>
                <counts group_id="E2" events="315" subjects_affected="108" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Oral hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Salivary gland disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="98" subjects_affected="54" subjects_at_risk="138"/>
                <counts group_id="E2" events="89" subjects_affected="46" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="138"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="138"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="47" subjects_affected="28" subjects_at_risk="138"/>
                <counts group_id="E2" events="85" subjects_affected="29" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="768" subjects_affected="124" subjects_at_risk="138"/>
                <counts group_id="E2" events="711" subjects_affected="126" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="138"/>
                <counts group_id="E2" events="28" subjects_affected="21" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>General symptom</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Ill-defined disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="138"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="44" subjects_affected="21" subjects_at_risk="138"/>
                <counts group_id="E2" events="46" subjects_affected="28" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Visceral edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="138"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="9" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Immune system disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Gingival infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="138"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Peripheral nerve infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Rhinitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="138"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="138"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="138"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="138"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Aortic injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="10" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dermatitis radiation</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="138"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Intraoperative breast injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pharyngeal anastomotic leak</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Radiation recall reaction (dermatologic)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="138"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="104" subjects_affected="27" subjects_at_risk="138"/>
                <counts group_id="E2" events="87" subjects_affected="35" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="44" subjects_affected="14" subjects_at_risk="138"/>
                <counts group_id="E2" events="41" subjects_affected="12" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="77" subjects_affected="26" subjects_at_risk="138"/>
                <counts group_id="E2" events="78" subjects_affected="28" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="10" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="22" subjects_affected="7" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Leukocyte count decreased</sub_title>
                <counts group_id="E1" events="129" subjects_affected="38" subjects_at_risk="138"/>
                <counts group_id="E2" events="149" subjects_affected="35" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="99" subjects_affected="22" subjects_at_risk="138"/>
                <counts group_id="E2" events="103" subjects_affected="21" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="147" subjects_affected="70" subjects_at_risk="138"/>
                <counts group_id="E2" events="202" subjects_affected="75" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="138"/>
                <counts group_id="E2" events="30" subjects_affected="13" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="20" subjects_affected="10" subjects_at_risk="138"/>
                <counts group_id="E2" events="39" subjects_affected="14" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="17" subjects_affected="9" subjects_at_risk="138"/>
                <counts group_id="E2" events="21" subjects_affected="8" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkalosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="71" subjects_affected="27" subjects_at_risk="138"/>
                <counts group_id="E2" events="78" subjects_affected="27" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="138"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="52" subjects_affected="16" subjects_at_risk="138"/>
                <counts group_id="E2" events="89" subjects_affected="22" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="14" subjects_at_risk="138"/>
                <counts group_id="E2" events="32" subjects_affected="15" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="138"/>
                <counts group_id="E2" events="14" subjects_affected="7" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="21" subjects_affected="13" subjects_at_risk="138"/>
                <counts group_id="E2" events="30" subjects_affected="21" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="23" subjects_affected="11" subjects_at_risk="138"/>
                <counts group_id="E2" events="22" subjects_affected="16" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="138"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Fibrosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Joint disorder</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" events="69" subjects_affected="38" subjects_at_risk="138"/>
                <counts group_id="E2" events="103" subjects_affected="45" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="138"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Muscle weakness upper limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Musculoskeletal deformity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="107" subjects_affected="39" subjects_at_risk="138"/>
                <counts group_id="E2" events="132" subjects_affected="48" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="138"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Neck soft tissue necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="36" subjects_affected="23" subjects_at_risk="138"/>
                <counts group_id="E2" events="34" subjects_affected="18" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="34" subjects_affected="23" subjects_at_risk="138"/>
                <counts group_id="E2" events="35" subjects_affected="23" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Facial nerve disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="72" subjects_affected="40" subjects_at_risk="138"/>
                <counts group_id="E2" events="79" subjects_affected="38" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypoglossal nerve disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="138"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Mini mental status examination abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Neurological disorder NOS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Olfactory nerve disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="22" subjects_affected="11" subjects_at_risk="138"/>
                <counts group_id="E2" events="31" subjects_affected="15" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="352" subjects_affected="92" subjects_at_risk="138"/>
                <counts group_id="E2" events="436" subjects_affected="104" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Sinus pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Taste alteration</sub_title>
                <counts group_id="E1" events="37" subjects_affected="10" subjects_at_risk="138"/>
                <counts group_id="E2" events="62" subjects_affected="20" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="62" subjects_affected="15" subjects_at_risk="138"/>
                <counts group_id="E2" events="60" subjects_affected="23" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="42" subjects_affected="15" subjects_at_risk="138"/>
                <counts group_id="E2" events="50" subjects_affected="19" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="73" subjects_affected="30" subjects_at_risk="138"/>
                <counts group_id="E2" events="76" subjects_affected="43" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="6" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hemorrhage urinary tract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Kidney pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Urine discoloration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Urogenital disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" events="38" subjects_affected="28" subjects_at_risk="138"/>
                <counts group_id="E2" events="46" subjects_affected="28" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Irregular menstruation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Lactation disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Ovulation pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Reproductive tract disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Uterine hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Vaginal dryness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="138"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Vaginal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Vaginal mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Vaginal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="138"/>
                <counts group_id="E2" events="23" subjects_affected="16" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Bronchial hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="54" subjects_affected="27" subjects_at_risk="138"/>
                <counts group_id="E2" events="40" subjects_affected="21" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="40" subjects_affected="24" subjects_at_risk="138"/>
                <counts group_id="E2" events="50" subjects_affected="25" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hemorrhage nasal</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="138"/>
                <counts group_id="E2" events="21" subjects_affected="13" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hiccough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Laryngeal edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Laryngeal mucositis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="138"/>
                <counts group_id="E2" events="24" subjects_affected="13" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pharyngeal mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="138"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pulmonary hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="23" subjects_affected="11" subjects_at_risk="138"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Voice alteration</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="588" subjects_affected="93" subjects_at_risk="138"/>
                <counts group_id="E2" events="579" subjects_affected="98" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="138"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="138"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hand-and-foot syndrome</sub_title>
                <counts group_id="E1" events="26" subjects_affected="17" subjects_at_risk="138"/>
                <counts group_id="E2" events="28" subjects_affected="15" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" events="71" subjects_affected="33" subjects_at_risk="138"/>
                <counts group_id="E2" events="93" subjects_affected="42" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="138"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Photosensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="138"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="138"/>
                <counts group_id="E2" events="29" subjects_affected="16" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Rash desquamating</sub_title>
                <counts group_id="E1" events="42" subjects_affected="24" subjects_at_risk="138"/>
                <counts group_id="E2" events="59" subjects_affected="40" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Scalp pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="6" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="22" subjects_affected="12" subjects_at_risk="138"/>
                <counts group_id="E2" events="15" subjects_affected="9" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="24" subjects_affected="9" subjects_at_risk="138"/>
                <counts group_id="E2" events="60" subjects_affected="25" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Skin hypopigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Skin induration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="138"/>
                <counts group_id="E2" events="13" subjects_affected="7" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="101" subjects_affected="40" subjects_at_risk="138"/>
                <counts group_id="E2" events="101" subjects_affected="45" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="100" subjects_affected="25" subjects_at_risk="138"/>
                <counts group_id="E2" events="83" subjects_affected="24" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Peripheral ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="138"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Aman U. Buzdar, MD</name_or_title>
      <organization>University of Texas MD Anderson Cancer Center, Houston, TX, USA</organization>
      <phone>713-792-2817</phone>
      <email>abuzdar@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

